{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Phase+1b&page=38", "query": { "intervention": "Phase 1b", "page": 38 }, "page_size": 10 }, "pagination": { "page": 38, "page_size": 10, "total_count": 2481, "total_pages": 249, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Phase+1b&page=39&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Phase+1b&page=37&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-22T01:52:41.670Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01604863", "title": "A Study of HGS1036 in Combination With Chemotherapy in Subjects With Advanced Solid Malignancies", "overall_status": "SUSPENDED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Cancer" ], "interventions": [ { "name": "HGS1036 + Paclitaxel + Carboplatin", "type": "DRUG" }, { "name": "HGS1036 + Cisplatin + Etoposide", "type": "DRUG" }, { "name": "HGS1036 + Docetaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Human Genome Sciences Inc., a GSK Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 54, "start_date": "2012-06", "completion_date": "2014-07", "has_results": false, "last_update_posted_date": "2012-11-01", "last_synced_at": "2026-10-22T01:52:41.670Z", "location_count": 2, "location_summary": "Scottsdale, Arizona • Boston, Massachusetts", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT01604863" }, { "nct_id": "NCT04882163", "title": "Study to Evaluate Tolerability of Iberdomide (CC-220) in Combination With Polatuzumab Vedotin Plus Rituximab or Tafasitamab or Rituximab Plus Chemotherapy in B-cell Lymphoma", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Lymphoma, B-Cell" ], "interventions": [ { "name": "CC-220", "type": "DRUG" }, { "name": "Polatuzumab vedotin", "type": "DRUG" }, { "name": "Rituximab", "type": "DRUG" }, { "name": "Tafasitamab", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Bendamustine", "type": "DRUG" }, { "name": "Lenalidomide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Celgene", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2021-10-10", "completion_date": "2029-04-07", "has_results": false, "last_update_posted_date": "2021-10-05", "last_synced_at": "2026-10-22T01:52:41.670Z", "location_count": 3, "location_summary": "Boston, Massachusetts • Ann Arbor, Michigan • Sioux Falls, South Dakota", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Ann Arbor", "state": "Michigan" }, { "city": "Sioux Falls", "state": "South Dakota" } ], "official_url": "https://clinicaltrials.gov/study/NCT04882163" }, { "nct_id": "NCT04447287", "title": "A Study to Assess the Effect of a Single Dose of ASP8062 on the Multiple Dose Safety, Tolerability and Pharmacokinetics of Buprenorphine/Naloxone in Participants With Opioid Use Disorder", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Opioid Use Disorder" ], "interventions": [ { "name": "ASP8062", "type": "DRUG" }, { "name": "Placebo ASP8062", "type": "DRUG" }, { "name": "buprenorphine/naloxone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Astellas Pharma Global Development, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "60 Years", "sex": "ALL", "summary": "18 Years to 60 Years" }, "enrollment_count": 23, "start_date": "2020-06-29", "completion_date": "2020-11-25", "has_results": true, "last_update_posted_date": "2024-11-21", "last_synced_at": "2026-10-22T01:52:41.670Z", "location_count": 1, "location_summary": "Overland Park, Kansas", "locations": [ { "city": "Overland Park", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04447287" }, { "nct_id": "NCT04444284", "title": "Study of the Safety and Immunogenicity of an Intranasal Vaccine for Respiratory Syncytial Virus in Seropositive Children", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Respiratory Syncytial Virus Infections" ], "interventions": [ { "name": "Investigational RSV vaccine MV-012-968 (Dosage 1)", "type": "BIOLOGICAL" }, { "name": "Investigational RSV vaccine MV-012-968 (Dosage 2)", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "OTHER" }, { "name": "Investigational RSV vaccine MV-012-968 (Dosage 3)", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "Meissa Vaccines, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "15 Months", "maximum_age": "59 Months", "sex": "ALL", "summary": "15 Months to 59 Months" }, "enrollment_count": 34, "start_date": "2020-06-09", "completion_date": "2021-05-07", "has_results": false, "last_update_posted_date": "2021-06-29", "last_synced_at": "2026-10-22T01:52:41.670Z", "location_count": 3, "location_summary": "Norfolk, Nebraska • Omaha, Nebraska • Cincinnati, Ohio", "locations": [ { "city": "Norfolk", "state": "Nebraska" }, { "city": "Omaha", "state": "Nebraska" }, { "city": "Cincinnati", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT04444284" }, { "nct_id": "NCT01746784", "title": "Safety and Pharmacokinetic Study of N6022 in Subjects With Cystic Fibrosis Homozygous for the F508del-CFTR Mutation", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Cystic Fibrosis" ], "interventions": [ { "name": "N6022", "type": "DRUG" }, { "name": "Normal saline", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Nivalis Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 66, "start_date": "2014-02", "completion_date": "2014-05", "has_results": true, "last_update_posted_date": "2014-11-24", "last_synced_at": "2026-10-22T01:52:41.670Z", "location_count": 17, "location_summary": "Birmingham, Alabama • Anchorage, Alaska • Palo Alto, California + 14 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Palo Alto", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Denver", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT01746784" }, { "nct_id": "NCT02045732", "title": "A Study To Evaluate The Safety And Tolerability Of PF-06342674 (RN168) In Subjects With Multiple Sclerosis (MS)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Multiple Sclerosis" ], "interventions": [ { "name": "PF-06342674 0.25 mg/kg", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "BIOLOGICAL" }, { "name": "PF-06342674 1.5 mg/kg", "type": "BIOLOGICAL" }, { "name": "PF-06342674 6.0 mg/kg", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 4, "start_date": "2014-09", "completion_date": "2015-10", "has_results": true, "last_update_posted_date": "2017-01-16", "last_synced_at": "2026-10-22T01:52:41.670Z", "location_count": 8, "location_summary": "Albany, New York • Latham, New York • Cleveland, Ohio + 2 more", "locations": [ { "city": "Albany", "state": "New York" }, { "city": "Latham", "state": "New York" }, { "city": "Latham", "state": "New York" }, { "city": "Latham", "state": "New York" }, { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT02045732" }, { "nct_id": "NCT03724084", "title": "Pinometostat With Standard Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia and MLL Gene Rearrangement", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Acute Myeloid Leukemia" ], "interventions": [ { "name": "Cytarabine", "type": "DRUG" }, { "name": "Daunorubicin", "type": "DRUG" }, { "name": "Daunorubicin Hydrochloride", "type": "DRUG" }, { "name": "Pinometostat", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "14 Years", "maximum_age": null, "sex": "ALL", "summary": "14 Years and older" }, "enrollment_count": 6, "start_date": "2019-04-10", "completion_date": "2022-11-14", "has_results": true, "last_update_posted_date": "2025-06-18", "last_synced_at": "2026-10-22T01:52:41.670Z", "location_count": 3, "location_summary": "New Haven, Connecticut • Baltimore, Maryland • Columbus, Ohio", "locations": [ { "city": "New Haven", "state": "Connecticut" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT03724084" }, { "nct_id": "NCT07051252", "title": "A Study of HBS-201 (Pitolisant Delayed-release)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Narcolepsy" ], "interventions": [ { "name": "HBS-201", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Harmony Biosciences Management, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 46, "start_date": "2025-05-21", "completion_date": "2025-10-13", "has_results": false, "last_update_posted_date": "2025-12-12", "last_synced_at": "2026-10-22T01:52:41.670Z", "location_count": 15, "location_summary": "San Ramon, California • Brandon, Florida • Miami, Florida + 12 more", "locations": [ { "city": "San Ramon", "state": "California" }, { "city": "Brandon", "state": "Florida" }, { "city": "Miami", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Newton", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT07051252" }, { "nct_id": "NCT00626249", "title": "Single Dose, Single Administration Study of Technosphere Inhalation Powder in Diabetic Subjects With Mild or Moderate Kidney Disease Compared to Diabetic Subjects With Normal Kidney Function", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Mild Nephropathy", "Moderate Nephropathy", "Diabetes Mellitus" ], "interventions": [ { "name": "Technosphere Inhalation Powder", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Mannkind Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 36, "start_date": "2007-08", "completion_date": "2008-10", "has_results": false, "last_update_posted_date": "2013-12-17", "last_synced_at": "2026-10-22T01:52:41.670Z", "location_count": 3, "location_summary": "Minneapolis, Minnesota • Omaha, Nebraska • San Antonio, Texas", "locations": [ { "city": "Minneapolis", "state": "Minnesota" }, { "city": "Omaha", "state": "Nebraska" }, { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00626249" }, { "nct_id": "NCT03649321", "title": "Clinical Trial of Chemotherapy and Bemcentinib for Metastatic Pancreatic Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Cancer of Pancreas" ], "interventions": [ { "name": "Bemcentinib", "type": "DRUG" }, { "name": "Nab-paclitaxel", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Texas Southwestern Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 9, "start_date": "2019-01-03", "completion_date": "2022-06-27", "has_results": true, "last_update_posted_date": "2023-11-09", "last_synced_at": "2026-10-22T01:52:41.670Z", "location_count": 1, "location_summary": "Dallas, Texas", "locations": [ { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03649321" } ] }